Morria Receives Clearance For Phase II Contact Dermatitis Study

Morria Biopharmaceuticals has received written approval to initiate phase II clinical trial on its topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

The double-blind, placebo-controlled study on 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel. A previous pilot clinical study demonstrated that a topical preparation of MRX6, applied for 28 days, scored 69% improvement based on conventional Physician’s Assessment. The upcoming study will examine a 21 days regime and monitor pharmacokinetics and dose-response parameters.

Yuval Cohen, president of Morria Biopharmaceuticals, said: This upcoming trial marks an important milestone for Morria’s unique proprietary technology. Our aim is to continue expanding in the inflammatory skin disease area as well as accelerate our parallel program in the respiratory field such as allergic rhinitis and cystic fibrosis, and in gastro-intestinal inflammation. We expect more clinical trial in these fields to commence in the near future. These programs demonstrate the potent transformative application of our technology.”